LISTING OF THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of the claims in the application:

1-65. (canceled)

66. (currently amended) A method for administering an oligonucleotide into a lung of a mammal, said method comprises:

aerosolizing the oligonucleotide wherein the aerosol particles have a size of about 1 to about 5 microns; and

introducing the aerosolized oligonucleotide into the lung of the mammal, wherein said oligonucleotide comprises a first region consisting of ten contiguous 2'-deoxy nucleosides flanked by second and third wing regions, each of said second and third wing regions independently consisting of five 2'-O-methoxyethyl nucleosides ~~wherein the sugar moiety of at least one nucleoside unit of the oligonucleotide is a 2'-O-substituted nucleoside unit comprising a 2'-O-substituent wherein said 2'-O-substituent of the 2'-O-substituted nucleoside unit is a 2'-O-methoxyethyl~~, and the oligonucleotide is taken up by at least one cell type in the lung of the mammal.

67-69. (cancelled)

70. (previously presented) The method of claim 66 wherein at least one internucleotide linkage within said oligonucleotide is a phosphorothioate linkage.

71. (previously presented) The method of claim 66 wherein at least one internucleotide linkage within said oligonucleotide is a 3'-methylenephosphonate, a non-phosphorous containing oligonucleotide linkage, a 2'-5' linkage or is a 3'-deoxy-3'-amino phosphoramidate linkage.

72. (previously presented) The method of claim 66 wherein said oligonucleotide is in an aqueous media.

73. (previously presented) The method of claim 66 wherein said oligonucleotide is in a sterilized, pyrogen free water.

74. (previously presented) The method of claim 66 wherein said oligonucleotide is in a saline solution.

75. (previously presented) The method of claim 66 wherein said oligonucleotide is in a powder.

76.-77. (canceled)

78. (currently amended) A method for increasing uptake into lung cells of a phosphorothioate containing oligonucleotide delivered by pulmonary administration into lung cells comprising incorporation of a 2'-O- methoxyethyl modification into the oligonucleotide, wherein said oligonucleotide comprises a first region consisting of ten contiguous 2'-deoxy nucleosides flanked by second and third wing regions, each of said second and third wing regions independently consisting of five 2'-O-methoxyethyl nucleosides.

79. (new) The method of claim 78 wherein said oligonucleotide is in an aqueous media.

80. (new) The method of claim 78 wherein said oligonucleotide is in a sterilized, pyrogen free water.

81. (new) The method of claim 78 wherein said oligonucleotide is in a saline solution.

82. (new) The method of claim 78 wherein said oligonucleotide is in a powder.